Scientific Industries INC 8-K filings

Scientific Industries, Inc. has appointed Carr, Riggs & Ingram, LLC as its new independent registered public accounting firm, following the acquisition of its previous auditor's capital markets practice.

Scientific Industries, Inc. completed the sale of its Genie Division assets to Troemner, LLC for $9.6 million plus potential earn-outs, significantly improving its pro forma cash position and net income.

Scientific Industries, Inc. announced the appointment of Zachary Rovinsky as its new Chief Financial Officer and a change in its independent registered public accounting firm.

Scientific Industries, Inc. has divested its Genie Division of Benchtop Laboratory Equipment to Troemner, LLC for $9.6 million in cash plus an earn-out of up to $1.5 million.

Scientific Industries, Inc. extends employment agreements for its President/CEO and Chairman, while also appointing its President/CEO as interim CFO following the departure of Nicholas Lavacca.

Scientific Industries, Inc. has entered into a Securities Purchase Agreement to sell units consisting of common stock, pre-funded warrants, and warrants for a total consideration of $1.55 million.

Scientific Industries, Inc. announces the appointment of Nicholas Lavacca as its new Chief Financial Officer, effective April 1, 2025, replacing Reginald Averilla.

Scientific Industries Inc. has appointed Forvis Mazars as its new independent registered public accounting firm, effective June 1, 2024, following a merger involving Mazars USA.

Scientific Industries has appointed Michael Blechman to its Board of Directors, as well as to its audit, compensation, and nominating committees, effective April 12, 2024.

Marcus Frampton resigned from his position as a Class B Director of Scientific Industries' Board of Directors, effective April 4, 2024.

Scientific Industries has appointed John Nicols as a Class C Director and member of the audit and compensation committees, effective March 4, 2024.

Scientific Industries finalized a $7 million private placement, issuing shares and warrants to investors, with proceeds earmarked for working capital in its bioprocessing division.